StreetInsider.com News Articles

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:01:00 -0400

MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of September 2, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

The

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:01:00 -0400

The

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 08:00:00 -0400

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28^th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET).

A live audio webcast and an archive of the recording will be available through the investors page of InspireMD’s corporate website at https://investors.inspiremd.com.

To request a meeting or for more details about the conferences, please reach out to

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 08:00:00 -0400

A live audio webcast and an archive of the recording will be available through the investors page of InspireMD’s corporate website at https://investors.inspiremd.com.

To request a meeting or for more details about the conferences, please reach out to

InspireMD (NSPR) Tops Q2 EPS by 1c

Mon, 17 Aug 2026 07:55:59 -0400

InspireMD (NASDAQ: NSPR) reported Q2 EPS of ($0.17), $0.01 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $2.54 million.

For earnings history and earnings-related data on InspireMD (NSPR) click here.

Form 8-K InspireMD, Inc. For: Aug 17

Mon, 17 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26934743.html

Form 8-K InspireMD, Inc. For: Aug 17

Mon, 17 Aug 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26934743.html

InspireMD Reports Second Quarter 2026 Financial Results

Mon, 17 Aug 2026 07:00:00 -0400

- Company to host investor conference call today, August 17^th, at 8:30am EDT -

MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026.

Recent Business Highlights:

Generated revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of 2025. Robust growth of 21% in international markets was driven by broad-based

InspireMD Reports Second Quarter 2026 Financial Results

Mon, 17 Aug 2026 07:00:00 -0400

- Company to host investor conference call today, August 17^th, at 8:30am EDT -

Recent Business Highlights:

Generated revenue of $1.8 million in the second quarter of 2026, in line with the second quarter of 2025. Robust growth of 21% in international markets was driven by broad-based

Form 10-Q InspireMD, Inc. For: Jun 30

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931580.html

Form 10-Q InspireMD, Inc. For: Jun 30

Fri, 14 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260814/26931580.html

InspireMD to Announce Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:01:00 -0400

MIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its press release for its second quarter financial results on Monday August 17, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.

Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be

InspireMD to Announce Second Quarter 2026 Financial Results

Mon, 10 Aug 2026 16:01:00 -0400

Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 221,666 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of August 3, 2026, as an inducement material to the non-executive employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).

The

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 07 Aug 2026 16:01:00 -0400

The

InspireMD names Kathleen Kennedy as SVP of global sales and marketing

Thu, 30 Jul 2026 16:01:10 -0400

InspireMD, Inc. (Nasdaq: NSPR) has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing, the company announced July 30, 2026. Kennedy will report to CEO Marvin Slosman.

Kennedy previously served as Sales Director at InspireMD, where she supported the initial U.S. launch of the CGuard Prime carotid stent system. She most recently held the position of Vice President of Sales for North America at Omniscient Neurotechnology before rejoining InspireMD.

Kennedy brings more than 30 years of medical device sales leadership experience, with a focus on carotid intervention and carotid stenting. Earlier roles include Senior Area Director at Silk Road

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

Thu, 30 Jul 2026 16:01:00 -0400

Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime

MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard^® Prime carotid stent system for the prevention of stroke, today announced the appointment of accomplished commercial leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing, reporting to CEO Marvin Slosman. Ms. Kennedy brings more than 30 years of medical device sales leadership experience, including significant expertise in carotid intervention and carotid stenting. Having previously led regional sales

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

Thu, 30 Jul 2026 16:01:00 -0400

Ms. Kennedy returns to InspireMD having previously served as Sales Director supporting the initial U.S. launch of CGuard Prime

Form 8-K InspireMD, Inc. For: Jul 23

Wed, 29 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26836293.html

Form 8-K InspireMD, Inc. For: Jul 23

Wed, 29 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260729/26836293.html

Form 8-K InspireMD, Inc. For: Jul 17

Thu, 23 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260723/26808942.html

Form 8-K InspireMD, Inc. For: Jul 17

Thu, 23 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260723/26808942.html

Form 8-K InspireMD, Inc. For: Jun 26

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729207.html

Form 8-K InspireMD, Inc. For: Jun 26

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729207.html

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 12 Jun 2026 16:05:00 -0400

MIAMI, June 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to six (6) new non-executive employees in the aggregate amount of 91,161 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of June 12, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).